Table 2.
Number of isolates and minimal inhibitory concentration (MIC) of antifungal agents for Candida spp. from patients with COVID-19 and candiduria
| Species (number of isolates) | Antifungal | Range MIC | MIC50 | MIC90 | S (%) | I (%) | R (%) |
|---|---|---|---|---|---|---|---|
| C. albicans (n = 8) | Fluconazole | 0.06–0.25 | 0.125 | 0.25 | 100 | NA | 0 |
| Itraconazole | <0.03–0.25 | 0.125 | 0.20 | 100* | NA | 0 | |
| Voriconazole | 0.06–0.5 | 0.25 | 0.50 | 50 | 50 | 0 | |
| Caspofungin | <0.015–0.125 | 0.06 | 0.10 | 100 | 0 | 0 | |
| Amphotericin B | 0.5–1.0 | 1.0 | 1.0 | 100* | NA | 0 | |
| C. tropicalis (n = 5) | Fluconazole | 0.25–0.50 | 0.5 | 0.5 | 100 | 0 | 0 |
| Itraconazole | <0.03–0.125 | 0.093 | 0.125 | 100* | NA | 0 | |
| Voriconazole | 0.125–0.25 | 0.25 | 0.25 | 20 | 80 | 0 | |
| Caspofungin | 0.06–0.125 | 0.093 | 0.125 | 100 | 0 | 0 | |
| Amphotericin B | 0.25–2.0 | 1.0 | 2.0 | 100* | NA | 0 | |
| C. glabrata (n = 5) | Fluconazole | 0.50–8.0 | 2.0 | 5.6 | 100 | NA | 0 |
| Itraconazole | 0.06–1.0 | 0.25 | 0.70 | 100* | NA | 0 | |
| Voriconazole | 0.125–4.0 | 0.5 | 2.8 | NA | NA | NA | |
| Caspofungin | 0.03–0.5 | 0.5 | 0.5 | 60 | 0 | 40 | |
| Amphotericin B | 0.5–2.0 | 0.5 | 1.60 | 100* | NA | 0 |
*Epidemiological cutoff (Pfaller et al., 2012). MIC Minimal inhibitory concentration; S susceptible; I intermediate; R resistant; NA not available. MIC is represented by μg/mL. Antifungal susceptibility (S, I, or R) is represented by the percentage of isolates for each agent